Randomized studies examining VEGF/VEGFR inhibition in patients with BrMs are needed to further evaluate if targeting this pathway is efficacious in preventing the development of BrMs in nonsquamous NSCLC [133]. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.